Fly News Breaks for December 13, 2019
Dec 13, 2019 | 07:20 EDT
Oppenheimer analyst Mark Breidenbach upgraded bluebird bio to Outperform from Perform with a $135 price target. In a research note to investors, Breidenbach says that given registration-enabling data for ide-cel in hand and undeniably positive updates for lentiglobin/Zynteglo presented at the American Society of Hematology meeting, he anticipates less headwind for bluebird heading into 2020. The analyst expects pivotal data from KarMMa to support FDA approval of ide-cel by late 2020, and believes new data from competing products could help calibrate expectations for its commercial potential.
News For BLUE From the Last 2 Days
There are no results for your query BLUE